Foghorn Therapeutics ( (FHTX) ) has provided an announcement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Foghorn Therapeutics has unveiled its strategic roadmap, emphasizing the advancement of its precision therapeutics pipeline, with a particular focus on oncology. The company is progressing multiple high-value assets into the clinic, including selective inhibitors and degraders for challenging targets like SMARCA2, EP300, and ARID1B, aiming to deliver first-in-class therapies with broad applications and potential blockbuster status.
More about Foghorn Therapeutics
Foghorn Therapeutics is a pioneering company in the field of chromatin biology, a promising area for therapeutic development, especially in oncology. The company focuses on precision therapeutics, targeting chromatin regulatory systems to treat a wide range of cancers, potentially impacting up to 50% of tumors.
YTD Price Performance: -17.83%
Average Trading Volume: 151,915
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $294.6M
Learn more about FHTX stock on TipRanks’ Stock Analysis page.
